By Jennifer Ahlstrom | Posted - Jul 22nd, 2020

 

 

 

 

Selinexor (XPOVIO) Submits FDA Application for Use at First Myeloma Relapse

Karyopharm Therapeutics has submitted a supplemental New Drug Application to the FDA looking for approval of the use of selinexor (XPOVIO) at first relapse for myeloma patients. 

Results from the BOSTON study, which combined selinexor with bortezomib and dexamethasone, supported the application request. The FDA is expected to make a decision in the first quarter of 2021. 

In the BOSTON trial, selinexor in the triplet combination was better than bortezomib and dex alone. The study results were published at the recent ASCO conference. 

  Seli/Velcade/dex Velcade/dex
Progression Free Survival 13.93 months 9.46 months
Overall Response Rate 76.4% 62.3%

 

Interestingly, the combination of selinexor with Velcade reduced the incidence of neuropathy, a common side effect with Velcade. Other noteworthy side effects (over grade 3) included:  

  Seli/Velcade/dex Velcade/dex
Low platelet counts 35.9% 15.2%
Fatigue 11.3% .5%
Nausea 7.7% 0%

 

“This sNDA acceptance brings us one step closer to providing access to selinexor for a significantly larger patient population battling multiple myeloma,” said Sharon Shacham, PhD, MBA, founder, president and chief scientific officer, Karyopharm, in a statement. “If approved, we believe selinexor will become an important new, oral, once-weekly treatment option, used in combination with once-weekly Velcade, for patients with multiple myeloma after at least 1 prior line of therapy.”

 

Selinexor is already approved by the FDA for myeloma patients who have received more than four prior therapies and are refractory to an immunomodulator, a proteasome inhibitor, and a monoclonal antibody. This would provide another all oral option for myeloma patients. 

 
Jennifer Ahlstrom
About the Author

Jennifer Ahlstrom - Jenny A - Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can help accelerate a cure by weighing in and participating in clinical trials. Founder of Myeloma Crowd, Myeloma Crowd Radio, HealthTree and the CrowdCare Foundation.

ADVERTISEMENT
ADVERTISEMENT
ADVERTISEMENT
 

Add a Comment


Anne - Very good article encouraging. I am a 2yr patient

 

MORE MYELOMA CROWD NEWS

Thanks to our site sponsors:

.